Comparative Pharmacology
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus TECHNESCAN HIDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus TECHNESCAN HIDA.
RADIOGENIX SYSTEM vs TECHNESCAN HIDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
None Documented
None Documented
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours.
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical